TRIAD-A: Treatment of Incontinence Associated Dermatitis - Automated

Sponsor
SchwabCare (Other)
Overall Status
Unknown status
CT.gov ID
NCT03046810
Collaborator
(none)
40
1
1
29
1.4

Study Details

Study Description

Brief Summary

Incontinence and the skin irritation (dermatitis) associated with it are common problems. Treatment of dermatitis is effective, but requires effective cleaning and application of a barrier substance to prevent further contact between urine or feces and the skin. Water based cleansing with the addition of a pH balanced cleanser is more effective than standard abrasive cleansing with paper or a cloth, and is better tolerated by those with skin irritation. Zinc oxide based barriers effectively promote healing and prevent further skin damage. Spray forms are less cumbersome and generally preferred, but are difficult to for the patient to apply independently given the challenge of accessing the perineum.

40 patients, recruited from 3 specialty pelvic floor centers and 1 assisted living center will be provided a device that cleans, dries, and applies zinc oxide barrier spray with each use of the toilet. Dermatitis will be evaluated at the beginning of the study, and at weeks 1, 2 and 6 by medical staff using a standard scale (The Kennedy Scale).Quality of life will be measured using a visual analog scale derived from the quality of life in incontinence scale.

The investigators hypothesize that the device will 1) effectively treat incontinence associated dermatitis, 2) prevent recurrence, and 3) be preferred over standard treatment.

Condition or Disease Intervention/Treatment Phase
  • Device: Wellness toileting system
N/A

Detailed Description

Incontinence and incontinence associated dermatitis (IAD) are common problems. A recent CDC study noted that up to 50% of noninstitutionalized patients aged 65 and older experienced episodes of incontinence at least monthly, and that 40% of those with incontinence develop secondary IAD The treatment of IAD is focused on effective cleaning and prevention of further exposure to irritant liquids and solids through barrier creams. Enzymatic washes have proven efficacy over soap and water, and zinc oxide is the standard of care for barrier function. Combined, effective cleansing and barrier use treats IAD in as little as 6 days, and effectively prevents recurrent skin damage. In one study, an effective preventive regimen of regularly applied skin therapy reduced the incidence of IAD in an at risk population from 25% to 5%. The combination of enzymatic skin cleanser and barrier protection is the standard of care for maintenance of skin integrity in patients with chronic urinary and fecal incontinence.

Adherence to prescribed regimens is a major barrier to regular use of substances applied to the perineum. Difficulty in accessing the perineum make adherence challenging to those with both full and limited mobility, often requiring assistance from a caregiver. The associated loss of independence and dignity are major detriments to quality of life. Novel formulations of zinc oxide, using aerosol based spray application, facilitate use and improve patient acceptance. In a 2014 nursing home based industry study, spray based zinc oxide was preferred by 80% of patients and caregivers, and improved treatment and prevention of IAD in 70% of the study participants.

Adequate cleansing and drying prior to the application of barrier products is key to effective prevention of skin breakdown. Water-based cleaning of the perineum after toileting has been demonstrated to improve hygiene over standard mechanical, paper-based cleansing, especially in those with limited mobility or incontinence. Evidence further demonstrates that the addition of pH balanced cleansers, applied without mechanical abrasion from cloths or wipes, advances hygiene and minimizes risk of secondary infection.

Study Aims

The aims of this study are to evaluate the efficacy of an automated delivery system for cleansing the perineum, and applying zinc oxide barrier spray to effectively treat and prevent incontinence associated dermatitis in a population with active or recurrent IAD. Secondary aims will be to assess preference for the automated delivery system over standard wash and manually applied barrier sprays.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Treatment of Incontinence Associated Dermatitis - Automated
Actual Study Start Date :
Apr 1, 2017
Anticipated Primary Completion Date :
Jul 1, 2019
Anticipated Study Completion Date :
Sep 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Wellness toileting system

This group will use the wellness toileting system for their perineal hygiene and treatment of dermatitis

Device: Wellness toileting system
This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
Other Names:
  • SchwabCare Wellness Toileting System
  • Outcome Measures

    Primary Outcome Measures

    1. Treatment of dermatitis [6 weeks]

      Improvement in the Kennedy Score for Dermatitis

    Secondary Outcome Measures

    1. Prevention of recurrent dermatitis [12 weeks]

      prevention of recurrent dermatitis by clinical criteria

    2. Improvement in quality of life [12 weeks]

      Assessed by visual analog scale derived from quality of life in incontinence scale

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Ability to give informed consent.

    • Active functional urinary or fecal incontinence

    • Kennedy Scale Grade >2 with active incontinence associated dermatitis

    • Willingness to have device installed in home/care center

    Exclusion Criteria:
    • Active perineal infection

    • Prior pelvic radiation

    • Perineal surgery within the prior 6 months

    • Known allergy or sensitivity to applied agents

    • Treatment for dermatitis within the prior 2 weeks.

    • Pre-existing pressure ulcer stage 2-4

    • Weight exceeding 300 pounds

    • Known allergy or hypersensitivity to cleanser or zinc oxide barrier spray

    • Home bathroom needs excessive upgrades, or needs ownership authorization

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Skyline Urology Torrance California United States 90505

    Sponsors and Collaborators

    • SchwabCare

    Investigators

    • Principal Investigator: Richard S Tilson, MD MPH, Director of Clinical Investigation

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    SchwabCare
    ClinicalTrials.gov Identifier:
    NCT03046810
    Other Study ID Numbers:
    • SC-01
    First Posted:
    Feb 8, 2017
    Last Update Posted:
    May 31, 2018
    Last Verified:
    May 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 31, 2018